Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

18.37 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35% ↗

January 23, 2025

Via The Motley Fool

Why Summit Therapeutics Stock Is Jumping Today ↗

January 21, 2025

Via The Motley Fool

8 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2025

Via Benzinga

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2025

From Summit Therapeutics Inc.

Via Business Wire

Why Summit Therapeutics Rocketed 584% in 2024 ↗

January 15, 2025

Via The Motley Fool

Where Will Summit Therapeutics Be in 5 Years? ↗

December 20, 2024

Via The Motley Fool

How Is The Market Feeling About Summit Therapeutics? ↗

December 13, 2024

Via Benzinga

BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst ↗

January 10, 2025

Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025.

Via Benzinga

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

January 08, 2025

Via Benzinga

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside ↗

January 07, 2025

Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments.

Via Benzinga

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 07, 2025

From Summit Therapeutics Inc.

Via Business Wire

Prediction: These 3 Healthcare Stocks Will Soar in 2025 ↗

January 04, 2025

Via The Motley Fool

3 Stocks That Could Be Monster Winners in 2025 ↗

December 29, 2024

Via The Motley Fool

3 Stocks That Could Turn $1,000 into $5,000 by 2030 ↗

December 20, 2024

Via The Motley Fool

3 No-Brainer Biotech Stocks to Buy With $200 Right Now ↗

December 18, 2024

Via The Motley Fool

2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street ↗

December 15, 2024

Via The Motley Fool

Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today ↗

December 14, 2024

Via The Motley Fool

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 13, 2024

From Summit Therapeutics Inc.

Via Business Wire

Why Summit Therapeutics Stock Rocketed 6% Higher on Friday ↗

December 06, 2024

Via The Motley Fool

Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher ↗

December 02, 2024

Via The Motley Fool

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

November 30, 2024

Via The Motley Fool

Summit Therapeutics to Present at Upcoming Investor Conferences

November 26, 2024

From Summit Therapeutics Inc.

Via Business Wire

3 Monster Stocks in the Making ↗

November 23, 2024

Via The Motley Fool

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 21, 2024

From Summit Therapeutics Inc.

Via Business Wire

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics ↗

November 14, 2024

Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China.

Via Investor's Business Daily

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential ↗

November 09, 2024

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus.

Via Benzinga

MarketBeat Week in Review – 11/4 - 11/8

November 09, 2024

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

Via MarketBeat

Topics Economy Government

2 Hot Biopharma Stocks to Buy and Hold for 5 Years ↗

November 08, 2024

If you're patient, these businesses have a lot of promising projects in the works.

Via The Motley Fool

Why Summit Therapeutics Stock Was a Winner Today ↗

November 04, 2024

A cancer drug has vast potential for the company, says a pundit newly following it.

Via The Motley Fool

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo ↗

November 04, 2024

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.